30-day results of ADAPT-DES registry reported at TCT 2011

November 9, 2011, Cardiovascular Research Foundation

The relationship of platelet responsiveness to antiplatelet medications; and, the correlation of poor response, and overall platelet aggregation while on dual antiplatelet therapy to the risk of drug-eluting stent thrombosis after 30 days was examined in ADAPT-DES, the largest registry to date to fully examine these relationships.

Results of ADAPT-DES (Assessment of Dual with Drug-Eluting Stents) were presented today at the 23rd annual Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

While prior studies have emphasized the absolute level of platelet activation/aggregation to antiplatelet medications, the role of the baseline level of platelet activation and the percentage of platelet inhibition in response to these therapies have largely been unstudied prior to ADAPT-DES.

In addition, the impact of poor platelet response to aspirin, and overall platelet aggregation while on dual antiplatelet therapy (DAPT) on the risk of stent has not been fully examined.

In the registry, 8,575 patients undergoing percutaneous (PCI) with drug-eluting stents were enrolled at 11 sites between January 2008 and September 2010. The researchers assessed platelet to aspirin and clopidogrel as well as overall platelet with the VerifyNow Aspirin, P2Y12, and IIb//IIIa tests after successful implantation of drug-eluting stents. Definite or probable stent thrombosis occurred in 39 patients (0.46%) after 30 days.

The researchers found that absolute and relative levels of platelet in response to ADP as assessed by the VerifyNow P2Y12 test are powerful independent predictors of stent thrombosis within 30 days, with a significant proportion of events independently attributable to hyoporesponsivenes.

In contrast, the baseline level of platelet P2Y12 response, as well as aspirin and overall platelet responsiveness after DAPT loading as assessed by VerifyNow were not shown to be related to the 30-day rate of stent thrombosis.

"These results suggest that agents which more effectively inhibit ADP-induced platelet activation should reduce 30-day stent thrombosis when applied to large patient populations," said lead investigator, Gregg W. Stone, MD. Dr. Stone is Director of Cardiovascular Research and Education at NewYork-Presbyterian Hospital/Columbia University Medical Center and Professor of Medicine, Division of Cardiology at Columbia University College of Physicians and Surgeons. Dr. Stone also serves as Co-Director, Medical Research & Education Division at the Cardiovascular Research Foundation.

"However, the modest sensitivity and specificity of platelet function testing, coupled with the low prevalence of events, implies that testing of platelet ADP antagonist responsiveness is unlikely to provide useful information to guide clinical decision-making in most individual patients for the prevention of stent thrombosis at 30 days," said Dr. Stone.

"The degree of platelet responsiveness to antiplatelet loading is useful to predict 30-day stent thrombosis in diabetic and non-diabetic patients, as well as those with ACS, but may have less clinical utility in patients with stable coronary artery disease (CAD)," Dr. Stone said.

"There was a low stent thrombosis rate in patients with stable CAD, which coupled with the poor prognostic utility of platelet function testing in this setting, suggests that assessing DAPT response in patients without ACS undergoing PCI is unlikely to provide incremental clinical utility. The relationship between platelet responsiveness testing and the occurrence of late and very late stent thrombosis, in patients who have maintained and discontinued DAPT, will be assessed during the two-year clinical follow-up phase of the ADAPT-DES study."

Explore further: Lower achieved platelet reactivity associated with better cardiovascular

Related Stories

Lower achieved platelet reactivity associated with better cardiovascular

August 30, 2011
Compared to patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence of cardiovascular death, heart attack and stent ...

Antiplatelets: 1 person, 1 dose?

April 14, 2011
An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, ...

Results of the DESERT registry reported at TCT 2011

November 9, 2011
The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.